B1931022

An Open-Label, Randomized Phase 3 Study Of Inotuzumab Ozogamicin Compared To A Defined Investigator's Choice In Adult Patients With Relapsed Or Refractory CD22-Positive Acute Lymphoblastic Leukemia (ALL)

Participating sites in Europe

Please find below the participating site across Europe.

Participating sites in Europe (61KB)

B1931022

About us

The objective of the European LeukemiaNet is to integrate the leading leukemia trial groups (CML, AML, ALL, CLL, MDS, CMPD), their interdisciplinary partners (diagnostics, treatment research, registry, guidelines), industry and SMEs across Europe to form a cooperative network for advancements in leukemia-related research and health care and cure.

Lastest Posts

Kontakt-Info

ELN-Foundation
Im Langgewann 45
69469 Weinheim, Germany

Hehlmann.ELN@gmail.com

B1931022

About us

Lastest Posts

Links

Kontakt-Info